argenx: EMA committee recommends approval of argenx's Vyvgart subcutaneous injection for chronic inflammatory demyelinating polyneuropathy

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the Committee for Medicinal Products for Human Use (CHMP) of the